AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
Short the launch starts early for Urovant
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Are the big corporate venture arms retreating?
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Asco-GU 2019 – Bayer and Orion have their work cut out with darolutamide
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
Upcoming events – cancer readouts for Merck & Co and Seattle
Merck & Co awaits full Keynote-426 data with Keytruda plus Inlyta, while Seattle Genetics looks beyond Adcetris with enfortumab vedotin.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Titan could give Erleada a fighting chance
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
Ash 2018 – Targeted AML trial expands its Beat
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.